LIG4 and leukemia: Currently, clinical trials of selective DNA-PKi are followed by M3814 (also known as Nedisertib and Peposertib) for treating adult solid tumours and leukaemia in combination with or without other therapies [14], whereas a selective LIG4 inhibitor is not currently available.